Revolutionizing Treatment with Bispecific Therapies: Navigating the Challenges Ahead
By decade’s end, approval of additional bispecifics is expected for hematological malignancies, solid tumors, and non-oncology conditions such as inflammatory, autoimmune, neurodegenerative and vascular diseases, and ocular disorders and infections.